ES3011716T3 - 3-sulfopropanoic acid for treating neurodegenerative disorders - Google Patents

3-sulfopropanoic acid for treating neurodegenerative disorders Download PDF

Info

Publication number
ES3011716T3
ES3011716T3 ES19752795T ES19752795T ES3011716T3 ES 3011716 T3 ES3011716 T3 ES 3011716T3 ES 19752795 T ES19752795 T ES 19752795T ES 19752795 T ES19752795 T ES 19752795T ES 3011716 T3 ES3011716 T3 ES 3011716T3
Authority
ES
Spain
Prior art keywords
spa
subject
disease
mec
csf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19752795T
Other languages
English (en)
Spanish (es)
Inventor
John Hey
Petr Kocis
Martin Tolar
Neil William Flanzraich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alzheon Inc
Original Assignee
Alzheon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alzheon Inc filed Critical Alzheon Inc
Application granted granted Critical
Publication of ES3011716T3 publication Critical patent/ES3011716T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
ES19752795T 2018-08-01 2019-07-30 3-sulfopropanoic acid for treating neurodegenerative disorders Active ES3011716T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862713061P 2018-08-01 2018-08-01
PCT/US2019/044023 WO2020028290A1 (en) 2018-08-01 2019-07-30 Methods for treating neurodegenerative disorders

Publications (1)

Publication Number Publication Date
ES3011716T3 true ES3011716T3 (en) 2025-04-08

Family

ID=67614642

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19752795T Active ES3011716T3 (en) 2018-08-01 2019-07-30 3-sulfopropanoic acid for treating neurodegenerative disorders

Country Status (27)

Country Link
US (2) US12083082B2 (https=)
EP (1) EP3829563B1 (https=)
JP (1) JP7573512B2 (https=)
KR (1) KR102716959B1 (https=)
CN (1) CN112867485A (https=)
AU (1) AU2019315853B2 (https=)
BR (1) BR112021001739A2 (https=)
CL (1) CL2021000269A1 (https=)
DK (1) DK3829563T3 (https=)
EA (1) EA202190406A1 (https=)
ES (1) ES3011716T3 (https=)
FI (1) FI3829563T3 (https=)
HR (1) HRP20250206T1 (https=)
HU (1) HUE070101T2 (https=)
IL (1) IL280424B2 (https=)
LT (1) LT3829563T (https=)
MX (1) MX2021001287A (https=)
MY (1) MY206530A (https=)
PH (1) PH12021550213A1 (https=)
PL (1) PL3829563T3 (https=)
PT (1) PT3829563T (https=)
RS (1) RS66516B1 (https=)
SG (1) SG11202100767XA (https=)
SI (1) SI3829563T1 (https=)
SM (1) SMT202500080T1 (https=)
UA (1) UA130011C2 (https=)
WO (1) WO2020028290A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021025504A2 (pt) * 2019-06-17 2022-04-26 Alzheon Inc Métodos para tratar distúrbios neurodegenerativos
MX2024007070A (es) * 2021-12-09 2024-08-22 Alzheon Inc Alz-801 para uso en el tratamiento de la enfermedad de alzheimer.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840294A (en) 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
PT2089417E (pt) 2006-10-12 2015-04-14 Bhi Ltd Partnership Métodos, compostos, composições e veículos para administrar o ácido 3-amino-1-propanossulfónico
WO2013177367A2 (en) 2012-05-23 2013-11-28 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
WO2014121083A1 (en) 2013-01-31 2014-08-07 President And Fellows Of Harvard College Methods of increasing neuronal connectivity and/or treating a neurodegenerative condition
CA2941415A1 (en) * 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
FI3347002T3 (fi) 2015-09-10 2023-08-10 Alzheon Inc Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa

Also Published As

Publication number Publication date
PH12021550213A1 (en) 2021-11-03
CA3108150A1 (en) 2020-02-06
US12083082B2 (en) 2024-09-10
KR102716959B1 (ko) 2024-10-11
CN112867485A (zh) 2021-05-28
FI3829563T3 (fi) 2025-02-17
AU2019315853B2 (en) 2025-05-01
EA202190406A1 (ru) 2021-10-15
MX2021001287A (es) 2021-07-15
JP2021533128A (ja) 2021-12-02
PT3829563T (pt) 2025-02-18
US20210315847A1 (en) 2021-10-14
SG11202100767XA (en) 2021-02-25
HUE070101T2 (hu) 2025-05-28
IL280424A (en) 2021-03-01
US20250213507A1 (en) 2025-07-03
KR20210039415A (ko) 2021-04-09
MY206530A (en) 2024-12-19
CL2021000269A1 (es) 2021-06-18
SI3829563T1 (sl) 2025-05-30
EP3829563B1 (en) 2024-11-20
UA130011C2 (uk) 2025-10-15
BR112021001739A2 (pt) 2021-04-27
IL280424B1 (en) 2024-09-01
RS66516B1 (sr) 2025-03-31
IL280424B2 (en) 2025-01-01
HRP20250206T1 (hr) 2025-04-11
PL3829563T3 (pl) 2025-04-07
AU2019315853A1 (en) 2021-03-18
WO2020028290A1 (en) 2020-02-06
DK3829563T3 (en) 2025-02-24
LT3829563T (lt) 2025-02-25
EP3829563A1 (en) 2021-06-09
JP7573512B2 (ja) 2024-10-25
SMT202500080T1 (it) 2025-03-12

Similar Documents

Publication Publication Date Title
US20250213507A1 (en) Methods for treating neurodegenerative disorders
US20260034088A1 (en) Sulfopropanoic acid derivatives for treating neurodegenerative disorders
CA3108150C (en) Methods for treating neurodegenerative disorders
HK40056250B (en) 3-sulfopropanoic acid for treating neurodegenerative disorders
HK40056250A (en) 3-sulfopropanoic acid for treating neurodegenerative disorders
HK40105684A (en) Sulfopropanoic acid derivatives for treating neurodegenerative disorders
HK40105684B (en) Sulfopropanoic acid derivatives for treating neurodegenerative disorders
EA048644B1 (ru) Способы лечения нейродегенеративных расстройств
HK40056251B (en) Sulfopropanoic acid derivatives for treating neurodegenerative disorders
HK40056251A (en) Sulfopropanoic acid derivatives for treating neurodegenerative disorders
EA052917B1 (ru) Способы лечения нейродегенеративных расстройств